Please use this identifier to cite or link to this item:
|Title:||Rs964184 (APOA5-A4-C3-A1) Is Related to Elevated Plasma Triglyceride Levels, but Not to an Increased Risk for Vascular Events in Patients with Clinically Manifest Vascular Disease|
|Authors:||van de Woestijne, Anton P.;van der Graaf, Yolanda;de Bakker, Paul I. W.;Asselbergs, Folkert W.;Spiering, Wilko;Visseren, Frank L. J.|
|subject:||Biology and Life Sciences;Biochemistry;Lipids;Lipid Metabolism;Medicine and Health Sciences;Cardiology;Epidemiology;Cardiovascular Disease Epidemiology;Genetic Epidemiology;Vascular Medicine;Vascular Diseases;Peripheral Vascular Disease;Atherosclerosis;Coronary Artery Disease;Stroke|
|Publisher:||Public Library of Science|
|Description:||Background: Single nucleotide polymorphisms in the APOA5-A4-C3-A1 gene complex are associated with elevated plasma triglycerides and elevated vascular risk in healthy populations. In patients with clinically manifest vascular disease, hypertriglyceridemia and metabolic syndrome are frequently present, but the contribution of these single nucleotide polymorphisms to plasma triglycerides, effect modification by obesity and risk of recurrent vascular events is unknown in these patients. Methods: Prospective cohort study of 5547 patients with vascular disease. Rs964184 (APOA5-A4-C3-A1 gene complex) was genotyped, and we evaluated the relation with plasma lipid levels, presence of metabolic syndrome and the risk for new vascular events. Results: The minor allele of rs964184 was strongly associated with log plasma triglycerides (β 0.12; 95%CI 0.10-0.15, p = 1.1*10−19), and was also associated with 0.03 mmol/L lower high-density lipoprotein-cholesterol (95%CI 0.01–0.04), and 0.14 mmol/L higher non-high-density lipoprotein-cholesterol (95%CI 0.09–0.20). The minor allele frequency increased from 10.9% in patients with plasma triglycerides <1 mmol/L to 24.6% in patients with plasma triglycerides between 4 and 10 mmol/L. The relation between rs964184 and plasma triglycerides was modified by body mass index in patients with one minor allele (β 0.02; (95%CI −0.04–0.09) if body mass index <24 kg/m2, β 0.17 (95%CI 0.12–0.22) if body mass index >27 kg/m2, p for interaction = 0.02). The prevalence of the metabolic syndrome increased from 52% for patients with two copies of the major allele to 62% for patients with two copies of the minor allele (p = 0.01). Rs964184 was not related with recurrent vascular events (HR 0.99; 95%CI 0.86–1.13). Conclusion: The single nucleotide polymorphism rs964184 (APOA5-A4-C3-A1) is associated with elevated plasma triglycerides concentrations in patients with clinically manifest vascular disease. In carriers of one minor allele, the effect on plasma triglycerides was modified by body mass index. There is no relation between rs964184 and recurrent vascular events in these patients.|
|Standard no:||van de Woestijne, Anton P., Yolanda van der Graaf, Paul I. W. de Bakker, Folkert W. Asselbergs, Wilko Spiering, and Frank L. J. Visseren. 2014. “Rs964184 (APOA5-A4-C3-A1) Is Related to Elevated Plasma Triglyceride Levels, but Not to an Increased Risk for Vascular Events in Patients with Clinically Manifest Vascular Disease.” PLoS ONE 9 (6): e101082. doi:10.1371/journal.pone.0101082. http://dx.doi.org/10.1371/journal.pone.0101082.|
|Appears in Collections:||HMS Scholarly Articles|
Files in This Item:
Click on the URI links for accessing contents.
Items in HannanDL are protected by copyright, with all rights reserved, unless otherwise indicated.